Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-12-04
2007-12-04
Saoud, Christine J. (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S192100, C514S002600, C514S012200, C530S350000, C530S387300, C536S023400
Reexamination Certificate
active
10988243
ABSTRACT:
Modified chimeric polypeptides with improved pharmacokinetics are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.
REFERENCES:
patent: 5712380 (1998-01-01), Kendall et al.
patent: 6011003 (2000-01-01), Charnock-Jones et al.
patent: 2005/0260203 (2005-11-01), Wiegand et al.
patent: 2006/0030529 (2006-02-01), Wiegand et al.
patent: 2006/0172944 (2006-08-01), Wiegand et al.
patent: WO97/44453 (1997-11-01), None
patent: WO98/13071 (1998-04-01), None
patent: WO99/03996 (1999-01-01), None
Witmer et al. (2003). Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 22:1-29.
Terman, B. I., et al, “Identification of a new endothelial cell growth factor receptor tyrosine kinase”, Oncogene (1991) 6:1677-1683.
Terman, B.I., et al, “Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor”, Biochem Biophys Res Comm (1992) 187(3):1579-1586.
Davis-Smyth, T., et al., 1996, “The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade”, The EMBO Journal 15(18):4919-4927.
Holash, J., et al., (2002) PNAS 99(17):11393-11398.
Heidaran, M.A., et al., (1990) J. Bio. Chem. 265(31):18741-18744.
Cunningham, S.A., et al., (1997) Biochem. Biophys. Res. Comm. 231:596-599.
Fuh, G., et al., (1998) J. Bio. Chem. 273(18):11197-11204.
Wiesmann, C., et al., (1997) Cell 91:695-704.
Barleon, B., et al., (1997) J. Bio. Chem. 272(16):10382-10388.
Davis-Smyth, T., et al., (1998) J. Bio. Chem. 273(6):3216-3222.
Papadopoulos Nicholas
Wiegand Stanley J.
Yancopoulos George D.
Gregg, Esq. Valeta
Lockard Jon M.
Regeneron Pharmaceuticals Inc.
Saoud Christine J.
LandOfFree
Methods of treating eye disorders with modified chimeric... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating eye disorders with modified chimeric..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating eye disorders with modified chimeric... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3896218